Bio-Rad Laboratories, Inc.

NYSE:BIO Stock Report

Market Cap: US$7.7b

Bio-Rad Laboratories Past Earnings Performance

Past criteria checks 1/6

Bio-Rad Laboratories's earnings have been declining at an average annual rate of -50.9%, while the Life Sciences industry saw earnings growing at 2% annually. Revenues have been declining at an average rate of 0.4% per year. Bio-Rad Laboratories's return on equity is 4.5%, and it has net margins of 12.5%.

Key information

-50.92%

Earnings growth rate

-51.11%

EPS growth rate

Life Sciences Industry Growth21.51%
Revenue growth rate-0.42%
Return on equity4.48%
Net Margin12.50%
Last Earnings Update30 Jun 2025

Recent past performance updates

Recent updates

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

Aug 07

Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Jul 14
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
User avatar

Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics

Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Apr 10
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

Mar 18
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28%

Feb 28
Some Confidence Is Lacking In Bio-Rad Laboratories, Inc. (NYSE:BIO) As Shares Slide 28%

Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation?

Feb 18
Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation?

Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

Jan 29

Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely

Jan 06
Getting In Cheap On Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Unlikely

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Dec 16
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis

Nov 25

Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

Nov 25
Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nov 04
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories: Overvalued Given Current Growth Prospects

Sep 23

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Sep 08
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar

Jul 14

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Bio-Rad Labs reports Q4 2022 results

Feb 16

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Revenue & Expenses Breakdown

How Bio-Rad Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:BIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 252,554319806293
31 Mar 252,541-2,164797292
31 Dec 242,567-1,844814296
30 Sep 242,580-779815279
30 Jun 242,563-1,326815231
31 Mar 242,605-322827237
31 Dec 232,671-637842247
30 Sep 232,720-159843250
30 Jun 232,769-428853273
31 Mar 232,779-191854272
31 Dec 222,802-3,627828257
30 Sep 222,805-6,021808236
30 Jun 222,871-1,930814234
31 Mar 222,896-91821233
31 Dec 212,9234,254851247
30 Sep 212,9806,659875268
30 Jun 212,8804,045857263
31 Mar 212,7014,098832251
31 Dec 202,5463,814799218
30 Sep 202,3803,521784212
30 Jun 202,2941,947786200
31 Mar 202,3291,579798198
31 Dec 192,3121,759825203
30 Sep 192,304377817198
30 Jun 192,289905822200
31 Mar 192,292574831197
31 Dec 182,289366835199
30 Sep 182,2941,277835199
30 Jun 182,2831,030827212
31 Mar 182,212767827227
31 Dec 172,160122803235
30 Sep 172,11017819232
30 Jun 172,08513814220
31 Mar 172,09726798207
31 Dec 162,06826786206
30 Sep 162,06798776204
30 Jun 162,02897772198
31 Mar 162,018108768194
31 Dec 152,019109762193
30 Sep 152,047103769193
30 Jun 152,10897787203
31 Mar 152,139100796212
31 Dec 142,17589810220
30 Sep 142,17980828217

Quality Earnings: BIO has a large one-off gain of $161.0M impacting its last 12 months of financial results to 30th June, 2025.

Growing Profit Margin: BIO became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have declined by 50.9% per year over the past 5 years.

Accelerating Growth: BIO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BIO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.9%).

Return on Equity

High ROE: BIO's Return on Equity (4.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/08 03:43
End of Day Share Price 2025/09/05 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Rad Laboratories, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Jon WoodBofA Global Research
Yuan ZhiB. Riley Securities, Inc.